MOLyF : Bone Marrow and Follicular Lymphoma

NCT06608147 | Recruiting

• 1 other identifier: 35RC24_9716_MOLyF
• Study Type: interventional
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

This is a prospective single-center study designed to assess potential differences in cell composition between bone marrows of patients with follicular lymphoma and those from control subjects. Follicular lymphoma is the most common indolent lymphoma. It is characterised by systematic relapses and bone marrow dissemination in 70% of patients at the time of diagnosis. Although relapses are thought to be related to refractory tumour cells nested in a supportive microenvironment in the bone marrow, the mechanisms involved are poorly understood. To study the specificities of the bone marrow of patients with follicular lymphoma, It is necessary to compare them with control samples. This study takes advantage of surgeries involving sternotomies to recover lost bone marrow and establish a bone marrow bank of patients without hematological disease. This bank will be used to set up control cohorts for other clinical trials involving patients with follicular lymphoma.

Conditions

Lymphoma, Follicular

Outcome Measures

Primary Outcomes (1)

• Flow cytometric quantification of cell populations

  Bone marrow cell populations of lymphoma-free patients (lymphoid cells, myeloid cells, stromal cells and adventitial cells) will be quantified using a flow cytometry panel and compared with those of Follicular Lymphoma patients.

  1 day

Study Arms (1)

Experimental

EXPERIMENTAL

Other: Sampling

Interventions

Sampling OTHER

sternal bone marrow aspiration

Experimental

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Major patient
• Patient hospitalized in the thoracic, cardiac and vascular surgery department for surgery involving a sternotomy
• Patient with free, informed, written consent
• Patient covered by a health insurance scheme

You may not qualify if:

• History of haematological malignancy or haemogram disturbance
• Immunomodulating treatment: immunosuppressants, corticoids, antineoplastics
• Persons covered by articles L. 1121-5 to L. 1121-8 and L. 1122-1-2 of the French Public Health Code (e.g. minors, protected adults, etc.)\].

Sponsors & Collaborators

• Rennes University Hospital: lead

Study Sites (1)

CHU Rennes

Rennes, 35009, France

RECRUITING

MeSH Terms

Conditions

Lymphoma, Follicular

Condition Hierarchy (Ancestors)

Lymphoma, Non-Hodgkin; Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• Juliette Ferrant, MD

  CHU Rennes

  STUDY CHAIR

Central Study Contacts

Juliette Ferrant, MD

CONTACT

0299282555; juliette.ferrant@chu-rennes.fr

Alexandra Guerrier

CONTACT

0299282555; alexandra.guerrier@chu-rennes.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 19, 2024
• First Posted: September 23, 2024
• Study Start: December 4, 2024
• Primary Completion (Estimated): October 1, 2034
• Study Completion (Estimated): October 1, 2034
• Last Updated: December 10, 2024

Record last verified: 2024-12

Locations

FR (1)